5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 367-371

  Terdiman, Jonathan P ^a   Steinbuch, Michael ^b   Blumentals, William A ^c   Ullman, Thomas A ^d   Rubin, David T ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 aminosalicylic acids; Case control study; Colitis; Colorectal cancer; Inflammatory bowel disease

Indexed keywords

BALSALAZIDE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DATA BASE; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; ULCERATIVE COLITIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; RISK; SULFASALAZINE; UNITED STATES;

EID: 34247564971     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20074     Document Type: Article

References (20)

1. Rutter MD, Sunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030-1038.
2. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmstead County, Minnesota. Gastroenterology. 2006;130:1039-1046.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
4. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
5. Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut. 1994;35:1507-1508.
6. van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126:1733-1739.
7. Bernstein CN, Eaden J, Steinhart AH, et al. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis. 2002;8:356-361.
8. Ryan BM, Russel MG, Langholz E, et al. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol. 2003;98:1682-1687.
9. Eaden J. The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease (review). Aliment Pharmacol Ther. 2003;18(Suppl 2):15-21.
10. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther. 1999;13:1397-1402.
11. Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy. 2000;32:245-254.
12. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
13. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14:145-153.
14. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784-2788.
15. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
16. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol, 2005;100:1345-1353.
17. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
18. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941-1949.
19. MacGregor DJ, Kim YS, Sleisenger MH, et al. Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+mouse. Int J Oncol. 2000;17:173-179.
20. Karlen P, Kornfeld D, Brostrom O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998;42:711-714.